These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38293566)

  • 1. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
    Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
    Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rising cases of drug-induced pulmonary fibrosis: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, 2000-2022.
    McCall KL; Hennig KR; Abe ZT; Dattler DN; Hurd KL; Portnoy SL; Zagoria ZJ
    Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5797. PubMed ID: 38680101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database.
    Yuan J; Lu H; Zuo X; Yin L; Pu Y; Zhang J
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70030. PubMed ID: 39385705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
    Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
    Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Li D; Qin C; Wang H; Du D; Wang Y; Du Q; Liu S
    Ther Adv Drug Saf; 2024; 15():20420986241274909. PubMed ID: 39247253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.
    Li Y; Sun S; Wu H; Zhao L; Peng W
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):71. PubMed ID: 39334280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS).
    Yu RJ; Krantz MS; Phillips EJ; Stone CA
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):819-829.e2. PubMed ID: 32992044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.
    Wu SN; Huang C; Wang YQ; Li X; Zhang SQ; Chen XD; Qin DY; Zhu L; Wen JY; Luo NC; Hu J; Liu Z
    Ther Adv Drug Saf; 2024; 15():20420986241285929. PubMed ID: 39429679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment.
    Li Y; Zhang N; Jiang T; Gan L; Su H; Wu Y; Yang X; Xiang G; Ni R; Xu J; Li C; Liu Y
    Pediatr Neurol; 2024 Sep; 158():71-78. PubMed ID: 38981277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
    Jiang A; Wei C; Zhu W; Wu F; Wu B
    Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
    Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM
    Ther Adv Drug Saf; 2023; 14():20420986231154075. PubMed ID: 36875514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.
    Long P; Li S; Pan L; Wang Y; Chen W; Wang X
    Front Pharmacol; 2024; 15():1378010. PubMed ID: 38766629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database.
    Hai L; Wu J; Xie Y
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70037. PubMed ID: 39420647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional diversity in drug-induced lung diseases among the USA, European Union, and Japan.
    Sato J; Sadachi R; Koyama T; Katsuya Y; Okada M; Yamamoto N
    Front Med (Lausanne); 2024; 11():1390083. PubMed ID: 39380740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.